New Jersey § 30:4d-17

§ 30:4d-17.

As used in this act: “ Beneficiary ” means a person participating in a State pharmaceutical benefits program. “ Board ” means the Drug Utilization Review Board established pursuant to section 2 of P.L.1998, c. 41 ( C.30:4D-17.17a ) in connection with State pharmaceutical benefits programs . “ Compendia ” means those resources widely accepted by the medical profession in the efficacious

use of drugs which is based on, but not limited to, these sources: the “American

Hospital Formulary Services Drug Information,” the “U.S. Pharmacopeia-Drug Information,”

the “American Medical Association Drug Evaluations,” and the peer-reviewed medical literature, and information provided from the manufacturers

of drug products. “ Criteria ” means those explicit and predetermined elements that are used to assess or measure

drug use on an ongoing basis to determine if the use is appropriate, medically necessary,

and not likely to result in adverse medical outcomes. “ Department ” means the Department of Human Services. “ Drug interactions ” means the occurrence when two or more drugs taken by a recipient lead to clinically

significant toxicity that is characteristic of one or any of the drugs present or

that leads to the interference with the effectiveness of one or any of the drugs. “ Drug-disease contraindication ” means the occurrence when the therapeutic effect of a drug is adversely altered

by the presence of another disease or condition. “ Intervention ” means a form of educational communication utilized by the board with a prescriber

or pharmacist to inform about or to influence prescribing or dispensing practices. “ Medicaid ” means the program established pursuant to P.L.1968, c. 413 ( C.30:4D-1 et seq. ). “ Overutilization or underutilization ” means the use or non-use of a drug in quantities such that the desired therapeutic

goal is not achieved. “ PAAD ” means the program of pharmaceutical assistance to the aged and disabled established

pursuant to P.L.1975, c. 194 ( C.30:4D-20 et seq. ). “ Prescriber ” means a person authorized by the appropriate State professional and occupational

licensing board to prescribe medication and devices. “ Prospective drug utilization review ” means that part of the drug utilization review program that occurs before the drug

is dispensed and is designed to screen for potential drug therapy problems based on

knowledge of the patient, the patient's continued drug use and the drug use criteria

and standards developed by the board. “ Retrospective drug utilization review ” means that part of the drug utilization review program that assesses or measures

drug use based on an historical review of drug use data against criteria and standards

developed by the board on an ongoing basis with professional input. “ Standards ” means the acceptable range of deviation from the criteria that reflects local medical

practice and that is tested on the beneficiary database. “ State pharmaceutical benefits program ” means the following programs: Medicaid, PAAD, the AIDS drug distribution program,

and any other State and federally funded pharmaceutical benefits program. “ Therapeutic appropriateness ” means drug prescribing and dispensing based on rational drug therapy that is consistent

with the criteria and standards developed pursuant to P.L.1993, c. 16 ( C.30:4D-17.16 et seq. ) and section 2 of P.L.1998, c. 41 ( C.30:4D-17.17a ) . “ Therapeutic duplication ” means the prescribing and dispensing of the same drug or of two or more drugs from

the same therapeutic class when overlapping time periods of drug administration are

involved and when the prescribing or dispensing is not medically indicated.